Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation
- 14 January 2003
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 55 (1) , 23-31
- https://doi.org/10.1046/j.1365-2125.2003.01735.x
Abstract
Aims To determine the population pharmacokinetics of theophylline during extracorporeal membrane oxygenation (ECMO) from routine monitoring data.Methods Retrospective data were collected from 75 term neonates and children (age range 2 days to 17 years) receiving continuous infusions of aminophylline (mean rate 9.2 ± 2.6 µg kg−1 min−1) during ECMO. A total of 160 plasma concentrations (range 1–8 per patient), sampled at time intervals ranging from 10 h to 432 h, were included. Population PK analysis and model building were carried out using WinNonMix Professional (Version 2.0.1). Cross‐validation was used to evaluate the validity and predictive accuracy of the model.Results A one‐compartment model with first order elimination combined with an additive error model was found to best describe the data. Of the covariables tested, bodyweight significantly influenced clearance and volume of distribution, whereas age was an important determinant of clearance, as adjudged by the differences in the −2 × log likelihood (P < 0.005) and the residual error value. The final model parameters were estimated as: clearance (l h−1) = 0.023 × bodyweight (kg) + 0.000057 × age (days) and volume of distribution (l) = 0.57 × bodyweight (kg). The interindividual variability in clearance and volume of distribution was 38% and 40%, respectively. The residual error corresponded to a standard deviation of 3.6 mg l−1. Cross‐validation revealed a median (95% confidence interval) model bias of 9.4% (2.9, 16.5%) and precision of 29.5% (24.8, 36.0%).Conclusions The estimated clearance is significantly lower, and volume of distribution higher, than previously reported in non‐ECMO patients of similar age. These differences are probably a result of the expanded circulating volume during ECMO and altered renal and hepatic physiology in this critically ill group. Large interindividual variability reflects the heterogeneous nature of patients treated on ECMO.Keywords
This publication has 40 references indexed in Scilit:
- Population Pharmacokinetics of Ifosfamide and its Dechloroethylated and Hydroxylated Metabolites in Children with Malignant DiseaseClinical Pharmacokinetics, 2001
- Population PharmacokineticsClinical Pharmacokinetics, 1999
- Vascular changes with in utero correction of diaphragmatic herniaJournal of Pediatric Surgery, 1994
- An introduction to mixed effect modeling: Concepts, definitions, and justificationJournal of Pharmacokinetics and Biopharmaceutics, 1991
- Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects modelsJournal of Pharmacokinetics and Biopharmaceutics, 1989
- The population pharmacokinetics of theophylline in neonates and young infantsJournal of Pharmacokinetics and Biopharmaceutics, 1989
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Estimation of population characteristics of pharmacokinetic parameters from routine clinical dataJournal of Pharmacokinetics and Biopharmaceutics, 1977
- The supra-additive natriuretic effect addition of theophylline ethylenediamine and bumetanide in congestive heart failureAmerican Heart Journal, 1977
- Pharmacokinetic analysis of the disposition of intravenous theophylline in young childrenThe Journal of Pediatrics, 1976